A Study to Investigate the Use of VH3810109 With or Without Fostemsavir (FTR) to Reduce the Size and Activity of the Viral Reservoir in People Living With HIV
NCT ID: NCT07053384
Last Updated: 2025-12-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE1
100 participants
INTERVENTIONAL
2025-07-10
2028-03-24
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Participants receiving SOC INSTI-based ART plus VH3810109
VH3810109
VH3810109 will be administered.
SOC INSTI-based ART
A SOC INSTI-based ART regimen will be administered.
Participants receiving SOC INSTI-based ART plus VH3810109 plus FTR
VH3810109
VH3810109 will be administered.
Fostemsavir (FTR)
Fostemsavir will be administered.
SOC INSTI-based ART
A SOC INSTI-based ART regimen will be administered.
Participants receiving standard of care (SOC) integrase strand transfer inhibitor (INSTI)-based ART
SOC INSTI-based ART
A SOC INSTI-based ART regimen will be administered.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
VH3810109
VH3810109 will be administered.
Fostemsavir (FTR)
Fostemsavir will be administered.
SOC INSTI-based ART
A SOC INSTI-based ART regimen will be administered.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Persons of any sex or gender are eligible. Note: Participants of childbearing potential (POCBP) are eligible to participate if not pregnant, not lactating, and agreeing to adhere to study requirements for use of contraception and pregnancy avoidance.
* Participant has a documented diagnosis of HIV-1 infection Note: Participants in Population 1 must have a documented positive HIV antibody result available for Screening.
Population 1 only:
* Plasma HIV-1 RNA \>=2000 copies/milliliter (c/mL) at Screening.
* CD4+ T cell count \>=300 cells/microliter (μL) at Screening.
* Antiretroviral treatment naïve, defined as no exposure to ART after a diagnosis of HIV-1 infection, prior to enrollment.
Population 2 only:
* Participant is stably virologically suppressed (plasma HIV-1 RNA \<50 c/mL).
* Documented evidence of uninterrupted treatment with oral non-boosted INSTI-based ART for at least 6 months prior to Screening, as well as uninterrupted treatment with ART (any guideline-recommended oral regimen) for at least 24 months prior to Screening.
* CD4+ T cell count \>=450 cells/μL at Screening.
* Body weight \>=50 kg to \<=115 kg.
* Participant is capable of giving written informed consent, which includes adherence to the requirements and restrictions listed in the consent form and in the protocol.
Exclusion Criteria
* Participant is pregnant, breastfeeding, or planning to become pregnant or breastfeed during the study.
* Participant has documented diagnosis of HIV-2 infection.
* Participant is known to have acquired HIV via perinatal transmission.
* Any evidence of a current or known past Center for Disease Control and Prevention (CDC) Stage 3 disease.
* Any ongoing malignancy or history of systemic cancers, such as Kaposi's sarcoma and lymphoma, or other virus-associated malignancies.
* Ongoing or clinically relevant pancreatitis.
* Current HIV-related kidney disease.
* History of or active HIV-associated dementia or progressive multifocal leukoencephalopathy.
CARDIAC \& CARDIOVASCULAR CONDITIONS
• Participants who are at clinically significant risk of cardiovascular disease.
* Ongoing or any lifetime history of clinically significant cardiovascular or cardiac disease.
* Confirmed QTcF value outside normal range at Screening or Day 1.
HEPATIC CONDITIONS
• History of clinically relevant hepatitis in the 6 months prior to Screening.
* Participants with severe hepatic impairment.
* Advanced MAFLD and advanced non-alcoholic steatohepatitis, if evidence for substantial fibrosis (fibrosis score ≥F2) or evidence of cirrhosis.
* Unstable liver disease.
* History of liver cirrhosis with or without hepatitis viral co-infection.
NEUROPSYCHIATRIC CONDITIONS
• Participants who pose a significant suicide risk.
LABORATORY DIAGNOSTIC ASSESSMENTS
* Participants who are experiencing (Population 1) or are known to have initiated ART during (Population 2) acute HIV infection.
* Any verified Grade 4 laboratory abnormality at Screening, excluding asymptomatic elevations of lipids or CPK.
* Alanine transferase (ALT) \>=3 times the upper limit of normal (ULN) at Screening.
* Estimated glomerular filtration rate (eGFR) of \<60 mL/min/1.73 m\^2.
* Hemoglobin \>=Grade 2 at Screening.
* Platelets \>=Grade 2 at Screening.
* Absolute Neutrophil Count (ANC) ≥Grade 2 at Screening.
* Any acute abnormality at Screening, which, in the opinion of the investigator, would preclude the participant's inclusion in an interventional clinical study.
Population 2 only • Two or more plasma HIV-1 RNA results \>=50 c/mL in the 18 months prior to Screening.
INFECTIOUS DISEASES
* Active hepatitis B virus (HBV) co-infection.
* Active hepatitis C virus (HCV) co-infection.
* Participant has untreated syphilis before enrolment.
* Known current untreated or incompletely treated active Mycobacterium TB infection.
ANTIRETROVIRAL RESISTANCE
• Known major resistance-associated mutations to second-generation INSTIs or to antiretroviral (ARV) agents from 2 or more drug classes.
PRIOR AND CONCOMITANT MEDICATIONS
* Prior use of any of the following agents:
o long-acting ARVs (any dose in the past 24 months or within 5 half-lives \[whichever is longer\])
o FTR (any lifetime use)
* HIV-1 immunotherapeutic vaccines or prophylactic vaccines (any lifetime use)
* HIV-1 monoclonal antibody therapy (any lifetime use).
* Prior receipt of any approved or experimental non-HIV vaccination within 2 weeks prior to study enrolment.
* History of systemic corticosteroids, immunosuppressive anti-cancer, interleukins, systemic interferons, or systemic chemotherapy, within 6 months prior to Screening.
* Participant has received an experimental drug or experimental vaccine within either 30 days, 5 half-lives of the test agent, or twice the duration of the biological effect of the test agent (whichever is longer), prior to enrolment.
* Treatment with any of the following agents within 30 days of enrolment:
o radiation therapy
o cytotoxic chemotherapeutic agents
* anti-tuberculosis therapy
* immunomodulators that alter immune responses such as chronic systemic corticosteroids, interleukins, or interferons.
* Participant is receiving any protocol-defined prohibited medication and is unwilling or unable to switch to an alternate medication. Prohibited medications must be stopped within 7 days (or 14 days if the drug is a potential CYP3A4 enzyme inducer) or 5 half-lives (whichever is longer), prior to enrolment.
Population 1 only • Known use of PrEP or PEP within \<30 days (for oral agents) or \<52 weeks (for LA parenteral agents) of HIV-1 diagnosis. Participants with a documented seronegative result \>=30 days after the last dose of oral PrEP or PEP (or \>=52 weeks after the last dose of LA PrEP) are not excluded.
Population 2 only
• Current use of NNRTI-containing ART.
OTHER EXCLUSIONS
* History or presence of allergy or intolerance to the study drugs or their components or drugs of their class, or a history of drug or other allergy that contraindicates study participation.
* Any condition which may interfere with the absorption, distribution, metabolism or excretion of the study drugs or render the participant unable to receive study drugs.
* Any pre-existing physical or mental condition (including substance use disorder) which, may interfere with the participant's ability to comply with the dosing schedule and/or protocol evaluations or which may compromise the safety of the participant.
* Participant is currently participating in, or anticipates being selected for, any other interventional study.
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
ViiV Healthcare
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
GSK Investigational Site
Bakersfield, California, United States
GSK Investigational Site
San Diego, California, United States
GSK Investigational Site
Ft. Pierce, Florida, United States
GSK Investigational Site
Orlando, Florida, United States
GSK Investigational Site
Chicago, Illinois, United States
GSK Investigational Site
Kansas City, Missouri, United States
GSK Investigational Site
St Louis, Missouri, United States
GSK Investigational Site
New York, New York, United States
GSK Investigational Site
Cincinnati, Ohio, United States
GSK Investigational Site
Philadelphia, Pennsylvania, United States
GSK Investigational Site
Pittsburgh, Pennsylvania, United States
GSK Investigational Site
Dallas, Texas, United States
GSK Investigational Site
Dallas, Texas, United States
GSK Investigational Site
Brussels, , Belgium
GSK Investigational Site
Ghent, , Belgium
GSK Investigational Site
Aarhus, , Denmark
GSK Investigational Site
Hvidovre, , Denmark
GSK Investigational Site
Rotterdam, , Netherlands
GSK Investigational Site
Barcelona, , Spain
GSK Investigational Site
Barcelona, , Spain
GSK Investigational Site
Barcelona, , Spain
GSK Investigational Site
Barcelona, , Spain
GSK Investigational Site
Barcelona, , Spain
GSK Investigational Site
Barcelona, , Spain
GSK Investigational Site
Córdoba, , Spain
GSK Investigational Site
La Laguna Santa Cruz, , Spain
GSK Investigational Site
Madrid, , Spain
GSK Investigational Site
Madrid, , Spain
GSK Investigational Site
Madrid, , Spain
GSK Investigational Site
Madrid, , Spain
GSK Investigational Site
Madrid, , Spain
GSK Investigational Site
Madrid, , Spain
GSK Investigational Site
Madrid, , Spain
GSK Investigational Site
Palma de Mallorca, , Spain
GSK Investigational Site
Palma de Mallorca, , Spain
GSK Investigational Site
Seville, , Spain
GSK Investigational Site
Valencia, , Spain
GSK Investigational Site
Valencia, , Spain
GSK Investigational Site
London, , United Kingdom
GSK Investigational Site
London, , United Kingdom
GSK Investigational Site
London, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
EU GSK Clinical Trials Call Center
Role: CONTACT
Phone: +44 (0) 20 89904466
Email: [email protected]
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
US GSK Clinical Trials Call Center
Role: primary
EU GSK Clinical Trials Call Centre
Role: backup
US GSK Clinical Trials Call Center
Role: primary
EU GSK Clinical Trials Call Centre
Role: backup
US GSK Clinical Trials Call Center
Role: primary
EU GSK Clinical Trials Call Centre
Role: backup
US GSK Clinical Trials Call Center
Role: primary
EU GSK Clinical Trials Call Centre
Role: backup
US GSK Clinical Trials Call Center
Role: primary
EU GSK Clinical Trials Call Centre
Role: backup
US GSK Clinical Trials Call Center
Role: primary
EU GSK Clinical Trials Call Centre
Role: backup
US GSK Clinical Trials Call Center
Role: primary
EU GSK Clinical Trials Call Centre
Role: backup
US GSK Clinical Trials Call Center
Role: primary
EU GSK Clinical Trials Call Centre
Role: backup
US GSK Clinical Trials Call Center
Role: primary
EU GSK Clinical Trials Call Centre
Role: backup
US GSK Clinical Trials Call Center
Role: primary
EU GSK Clinical Trials Call Centre
Role: backup
US GSK Clinical Trials Call Center
Role: primary
EU GSK Clinical Trials Call Centre
Role: backup
US GSK Clinical Trials Call Center
Role: primary
EU GSK Clinical Trials Call Centre
Role: backup
US GSK Clinical Trials Call Center
Role: primary
EU GSK Clinical Trials Call Centre
Role: backup
US GSK Clinical Trials Call Center
Role: primary
EU GSK Clinical Trials Call Centre
Role: backup
US GSK Clinical Trials Call Center
Role: primary
EU GSK Clinical Trials Call Centre
Role: backup
US GSK Clinical Trials Call Center
Role: primary
EU GSK Clinical Trials Call Centre
Role: backup
US GSK Clinical Trials Call Center
Role: primary
EU GSK Clinical Trials Call Centre
Role: backup
US GSK Clinical Trials Call Center
Role: primary
EU GSK Clinical Trials Call Centre
Role: backup
US GSK Clinical Trials Call Center
Role: primary
EU GSK Clinical Trials Call Centre
Role: backup
US GSK Clinical Trials Call Center
Role: primary
EU GSK Clinical Trials Call Centre
Role: backup
US GSK Clinical Trials Call Center
Role: primary
EU GSK Clinical Trials Call Centre
Role: backup
US GSK Clinical Trials Call Center
Role: primary
EU GSK Clinical Trials Call Centre
Role: backup
US GSK Clinical Trials Call Center
Role: primary
EU GSK Clinical Trials Call Centre
Role: backup
US GSK Clinical Trials Call Center
Role: primary
EU GSK Clinical Trials Call Centre
Role: backup
US GSK Clinical Trials Call Center
Role: primary
EU GSK Clinical Trials Call Centre
Role: backup
US GSK Clinical Trials Call Center
Role: primary
EU GSK Clinical Trials Call Centre
Role: backup
US GSK Clinical Trials Call Center
Role: primary
EU GSK Clinical Trials Call Centre
Role: backup
US GSK Clinical Trials Call Center
Role: primary
EU GSK Clinical Trials Call Centre
Role: backup
US GSK Clinical Trials Call Center
Role: primary
EU GSK Clinical Trials Call Centre
Role: backup
US GSK Clinical Trials Call Center
Role: primary
EU GSK Clinical Trials Call Centre
Role: backup
US GSK Clinical Trials Call Center
Role: primary
EU GSK Clinical Trials Call Centre
Role: backup
US GSK Clinical Trials Call Center
Role: primary
EU GSK Clinical Trials Call Centre
Role: backup
US GSK Clinical Trials Call Center
Role: primary
EU GSK Clinical Trials Call Centre
Role: backup
US GSK Clinical Trials Call Center
Role: primary
EU GSK Clinical Trials Call Centre
Role: backup
US GSK Clinical Trials Call Center
Role: primary
EU GSK Clinical Trials Call Centre
Role: backup
US GSK Clinical Trials Call Center
Role: primary
EU GSK Clinical Trials Call Centre
Role: backup
US GSK Clinical Trials Call Center
Role: primary
EU GSK Clinical Trials Call Centre
Role: backup
US GSK Clinical Trials Call Center
Role: primary
EU GSK Clinical Trials Call Centre
Role: backup
US GSK Clinical Trials Call Center
Role: primary
EU GSK Clinical Trials Call Centre
Role: backup
US GSK Clinical Trials Call Center
Role: primary
EU GSK Clinical Trials Call Centre
Role: backup
US GSK Clinical Trials Call Center
Role: primary
EU GSK Clinical Trials Call Centre
Role: backup
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2025-520629-19-00
Identifier Type: OTHER
Identifier Source: secondary_id
221794
Identifier Type: -
Identifier Source: org_study_id